HOME
PDF DOWNLOAD
PLAY LIST
Presentation file(PDF 1.2 MB)
from the beginning
Financial Results for 3Q FY2016 (April 1 to December 31, 2016)
Financial Results for 3Q FY2016
Financial Results for FY2016 Apr.-Dec.
Sales of Major Products in Japan
Sales of Major Products in North America & China
Segment Information
Ordinary income & Net income attributable to owners of the parent
Valuations and accounting procedures following the acquisition of Cynapsus
Financial Forecasts for FY2016
Financial Forecasts for FY2016
Clinical Development Status
Development Pipeline (1) (Psychiatry & Neurology Area) (as of January 27, 2017)
Development Pipeline (2) (Oncology Area) (as of January 27, 2017)
Development Pipeline (3) (Oncology & Others Area) (as of January 27, 2017)
Clinical Development Status (Major Changes since October 27, 2016)
Development Progress of Dasotraline
Napabucasin Presentation (Gastrointestinal Cancers Symposium (ASCO-GI 2017))
Profile of DSP-6745
Appendices
Changes from FY2015 3Q
Net Sales by Segment
Segment Information
Napabucasin - Clinical development progress (as of January 27, 2017)
Amcasertib, Napabucasin- Clinical development progress (as of January 27, 2017)
LATUDA (lurasidone) - Clinical development progress
Target submission date of key late-stage pipeline (Updated January 2017)
Product Launch Plan (Updated January 2017)
Regenerative Medicine / Cell Therapy Business Plan (Updated January 2017)
Disclaimer Regarding Forward-looking Statements
Sumitomo Dainippon Pharma
Q&A
Q&A 1
Q&A 2
Q&A 3
Q&A 4
Q&A 5
Q&A 6
Q&A 7
Q&A 8
January 27, 2017
Sumitomo Dainippon Pharma Co., Ltd.
Financial Results for 3Q FY2016 (April 1 to December 31, 2016)
1
/39
